This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunant, A. Search for Related Content PubMed PubMed Citation Articles by Dunant, A.

Adjuvant Chemotherapy for Non–Small Cell Lung Cancer: Contribution of the International Adjuvant Lung Trial

Authors' Affiliation: Departments of Biostatistics and Epidemiology (AD, JPP) and Medicine (TLC), Institut Gustave-Roussy, Villejuif, France

Requests for reprints: Ariane Dunant, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France; E-mail: adunant{at}igr.fr.

The recently reported International Adjuvant Lung Cancer Trial (IALT) was designed to assess the potential benefit of three to four cycles of adjuvant cisplatin-based chemotherapy after complete resection of non–small cell lung cancer (NSCLC). Each center predetermined the cisplatin dose (total 300-400 mg/m²), the combined drug (etoposide or a Vinca alkaloid), and the radiotherapy policy. From 1995 to 2000, 1,867 patients were randomized in 148 centers from 33 countries. On September 1, 2002, median follow-up was 56 months and >98% of patients had an updated follow-up. Overall survival was significantly different between the two arms: 5-year survival rate was 44.5% in the chemotherapy arm versus 40.4% in the control arm [relative risk = 0.86 (0.76-0.98), P < 0.03]. Disease-free survival, incidence of local recurrence, and incidence of distant metastases (but not brain metastases) were likewise significantly different, with an advantage for the chemotherapy arm. We concluded that adjuvant cisplatin-based chemotherapy in resected NSCLC should become part of the standard management of operable NSCLC. Two other recently reported randomized prospective studies also showed a significant benefit for postoperative platin-based doublets in stage IB and II NSCLC and confirmed the role of adjuvant chemotherapy as part of the treatment of these patients. The Lung Adjuvant Cisplatin Evaluation program, a pooled analysis of all recent platin-based adjuvant trials, and the IALT-Bio study, which will investigate over 30 markers in the IALT patients' specimens, should allow us to better define the populations more likely to benefit from postoperative chemotherapy.

This article has been cited by other articles:

				A. Bezjak, C. W. Lee, K. Ding, M. Brundage, T. Winton, B. Graham, M. Whitehead, D. H. Johnson, R. B. Livingston, L. Seymour, et al. Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non-Small-Cell Lung Cancer: Results From a Randomized Trial, JBR.10 J. Clin. Oncol., November 1, 2008; 26(31): 5052 - 5059. [Abstract] [Full Text] [PDF]

				G. M. Strauss, J. E. Herndon II, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. H. Gillenwater, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J. Clin. Oncol., November 1, 2008; 26(31): 5043 - 5051. [Abstract] [Full Text] [PDF]